Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Punicafolin is a hydrolyzable tannin, specifically an ellagitannin, naturally occurring in plants such as *Punica granatum* (pomegranate) and *Acer pseudosieboldianum* (Pax) Komarov. It is characterized by its potent anti-oxidative, anti-inflammatory, and anti-proliferative properties. Research indicates that punicafolin exhibits significant chemopreventive activity against prostate cancer by inducing apoptosis and inhibiting cell proliferation. While it belongs to a class of compounds known to modulate DNA methylation through the inhibition of DNA methyltransferases (DNMTs), its specific potency in this regard is often compared to related ellagitannins like geraniin or granatin B. It is primarily studied as a bioactive constituent of medicinal plant extracts for its potential in cancer prevention and treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on punicafolin.